Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALD518 in glucocorticoid-refractory acute GVHD
NCT01530256Phase 2Terminated
- Sponsor
- CSL Limited
- Start
- Mar 2012
- Primary completion
- Mar 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clazakizumab in Acute Graft-Versus-Host Disease (aGVHD), sponsored by CSL Limited. Started Mar 2012; status: terminated.
02
Drugs
clazakizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGVHD)
Beyond the preview
Go deeper on NCT01530256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01530256.